HLB announced that the clinical results of the Rivoceranib (Apatinib) study conducted in China confirmed several significant results, including complete remission in hepatocellular carcinoma. In addition, complete remission is observed for gastric cancer, lung cancer, esophageal cancer, and T-cell lymphoma, and the efficacy of Rivoceranib against various carcinomas is once again attracting attention.
A retrospective clinical trial in which Rivoceranib and Camrelizumab (PD-1 antibody) were administered in combination in 63 patients with advanced hepatocellular carcinoma at five hospitals including Nanfang Hospital of Southern Medical University, Shunde Hospital, and The First Affiliated Hospital of Sun Yat-sen University.
As a result, one complete remission case was observed, with 44% of Overall Response Rate (ORR), 75% of Disease Control Rate (DCR), 11.8 months of Progressive-Free Survival (mPFS), and 14.8 months of Overall Survival (mOS). In particular, the company explained that the clinical trial was very encouraging in that it was conducted on patients with Portal Bean Tumor Thrombus, which is known to be fast in progress and spread.
A HLB official said, "There are currently more than 300 clinical trials on Rivoceranib, including research clinical trials, and complete remission of various cancerous species is being observed one after another." And added, "In particular, high drug efficacy has been confirmed in the combination therapy of Rivoceranib and Camrelizumab, which is the same primary treatment for liver cell cancer that the company is focusing on."
HLB is currently conducting the third phase of global clinical trials in Korea, China, the United States, Europe, and Taiwan for a total of 510 people for the purpose of primary treatment of hepatocellular carcinoma. As of August, the recruitment rate of patients exceeded 50%.